Stay updated on PD-1 Combo in Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the PD-1 Combo in Renal Cancer Clinical Trial page.

Latest updates to the PD-1 Combo in Renal Cancer Clinical Trial page
- Check6 days agoChange DetectedThe record presents a Phase II study of D-CIK immunotherapy combined with pembrolizumab and axitinib for advanced renal cancer. It includes participant eligibility, study outcomes, and recruiting contact and location details.SummaryDifference46%

- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0. The page remains a 403 error page.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA general NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the unchanged 403 error page. The site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the full study record content and navigation with an error screen. This makes the study details on that page inaccessible.SummaryDifference18%

- Check62 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, signaling a version update rather than a substantive change to the study details.SummaryDifference0.1%

Stay in the know with updates to PD-1 Combo in Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-1 Combo in Renal Cancer Clinical Trial page.